文献速递泌尿生殖与妇科肿瘤放疗

宫颈癌放化疗联合图像引导自适应近距离放疗后输尿管狭窄的危险因素:EMBRACE研究结果

Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-11-10

EMBRACE研究纳入1860例接受外照射放疗、顺铂同步化疗及图像引导自适应近距离放疗的宫颈癌患者,中位随访34个月,31例发生3-4级输尿管狭窄,3年和5年发生率分别为1.7%和2.1%。诊断时T3-4期合并肾积水是唯一独立危险因素(P=0.01),该组3年和5年风险均为11.5%,显著高于T3-4期无肾积水组的2.2%和4.8%。

要点

  • 全组3-4级输尿管狭窄3年风险1.7%、5年风险2.1%,中位随访34个月共31例。
  • 诊断时T3-4期合并肾积水是唯一独立危险因素(P=0.01),3年和5年风险均为11.5%。
  • T1期(n=359)3年和5年风险分别为0.4%和1.0%,T2期(n=1085)均为1.0%。

核心结论

  • T1-2期宫颈癌患者发生严重至危及生命的输尿管狭窄罕见。
  • 诊断时T3-4期合并肾积水患者输尿管狭窄风险显著增加。

研究设计与样本

  • EMBRACE研究纳入1860例患者,治疗为外照射放疗(45-50 Gy分25-30次)、同步顺铂化疗及图像引导自适应近距离放疗。
  • 采用常见不良事件评价标准第3.0版评估3-4级输尿管狭窄,分析年龄、诊断时影像学肾积水、TNM分期、高危临床靶区、腹腔镜分期、化疗、靶区与危及器官放疗剂量、施源器类型、腔内与腔内/组织间插植技术及剂量率等危险因素。

主要发现

  • 中位随访34个月(范围2-163个月),31例患者诊断为3-4级输尿管狭窄。
  • 全组3年和5年3-4级输尿管狭窄实际风险分别为1.7%和2.1%。
  • 诊断时T3-4期合并肾积水是唯一独立危险因素(P=0.01)。
  • T1期(n=359)3年和5年风险分别为0.4%和1.0%,T2期(n=1085)分别为1.0%和1.0%。
  • T3-T4期无肾积水者(n=274)3年和5年风险分别为2.2%和4.8%,诊断时肾积水者(n=142)均为11.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ureteral stricture is a rare but severe side effect of radiation therapy for locally advanced cervical cancer. This report describes the incidence and risk factors for ureteral stricture in a large patient cohort treated with 3-dimensional image guided adaptive brachytherapy and radiochemotherapy within the EMBRACE studies. METHODS AND MATERIALS: A total of 1860 patients were included. Treatment consisted of external beam radiation therapy (45-50 Gy in 25-30 fractions), concomitant cisplatin, and image guided adaptive brachytherapy. Grade 3 to 4 ureteral strictures were assessed with Common Terminology Criteria for Adverse Events v. 3.0. Risk factors for grade 3 to 4 ureteral stricture were analyzed. These factors included age, hydronephrosis on imaging at time of diagnosis, TNM stage, high-risk clinical target volume, laparoscopic staging, chemotherapy, radiation therapy doses to targets and organs at risk, applicator type, intracavitary versus intracavitary/interstitial technique, and dose rate. RESULTS: At a median follow-up of 34 months (range, 2-163), 31 patients received diagnoses of grade 3 to 4 ureteral stricture. Actuarial 3- and 5-year risk for ureteral stricture grade 3 to 4 was 1.7% and 2.1%, respectively, for all patients. Advanced tumor stage T3-4 with hydronephrosis at diagnosis was the only independent risk factors for ureteral stricture (P = .01). Patients with TNM stage T1 (n = 359) had a low risk of 0.4% and 1.0% at 3 and 5 years, and those with T2 (n = 1085) had a low risk of 1.0% and 1.0% at 3 and 5 years, respectively. Patients (n = 274) with T3-T4 without hydronephrosis at diagnosis had a 3- and 5-year risk of 2.2% and 4.8%, respectively, compared with 11.5% and 11.5%, respectively, in those with baseline hydronephrosis (n = 142). CONCLUSIONS: Severe to life-threatening ureteral stricture occurs rarely in patients with locally advanced cervical cancer with T1-2 tumors. The risk for ureteral stricture is significantly increased in patients with T3-T4 tumors with hydronephrosis at diagnosis.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Fokdal L, Tanderup K, Pötter R, et al. Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies. Int J Radiat Oncol Biol Phys. 2018. PMID: 30419309. doi:10.1016/j.ijrobp.2018.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。